Press Releases

The patent includes classification techniques using single nucleotide polymorphisms (SNPs) in the ribosomal DNA of sepsis organisms Identification and classification of sepsis organisms leads to improved antibiotic decision-making SEATTLE, Nov. 21, 2019 – Immunexpress, Inc. today announced the U.S. Patent and Trademark Office (USPTO) has granted Patent No. U.S. 10,364,474 B2, which covers single nucleotide…

Immunexpress Announces Closing of Private Funding Round Funding will support the development of SeptiCyte™ RAPID through FDA 510(k) Clearance CE Marking of SeptiCyte™ RAPID anticipated in 1Q2020, FDA Clearance anticipated mid-2020 SEATTLE, Oct. 3, 2019 /PRNewswire/ — Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the closing of a major…

The addition represents the development of a global commercial framework in preparation for SeptiCyte™ RAPID launch Immunexpress, Inc. today announced that Jane Papadaki Markley has joined the company’s Executive Team as Vice President of Market Development and Commercial Operations. “Jane’s impressive ability to incorporate the commercial perspective into development strategies will be influential in our upcoming launch…

Immunexpress, Inc., a molecular diagnostics company based in Seattle, announced the publication of a study, in the Journal of Intensive Care, demonstrating the challenge physicians face in making accurate and consistent clinical diagnoses of sepsis in intensive care patients. Sepsis is an illness caused by the body’s overwhelming immune response to an infection, which can lead to tissue…

Immunexpress, Inc. today announced its partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which DRIVe will contribute $744,739 of a $3.2M project for the development and commercialization of Immunexpress’ SeptiCyte™ technology on the Biocartis Idylla™ platform. This development will result in a tool capable of a 90-minute, sample-to-result diagnosis in patients suspected of sepsis. DRIVe (Division of…

Patent Allowances Relate to SeptiCyte™ Technology Using Biomarkers These allowances further reinforce the claims of the core family of patents that support the Company’s gene expression technology in the detection of host response to sepsis SEATTLE, Sept. 24, 2018 – Immunexpress, Inc., today announced the receipt of ‘Notices of Allowance’ from both the U.S. Patent…

The allowance complements the Company’s growing patent portfolio of gene technology in the detection of host response to sepsis SEATTLE, July 26, 2018 /PRNewswire/ — Immunexpress, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 15/160749, “Validating biomarker measurement,” which relates to methods…

SEATTLE, July 10, 2018 /PRNewswire/ — Immunexpress, Inc. today announced that Fayyaz Memon, MBA, MS, has joined the company’s Executive Team as Vice President of Regulatory Affairs and Quality. “Mr. Memon arrives at a key time for the Company as we continue to fortify our leadership team with accomplished individuals well-versed in the life sciences industry,” Rolland D. Carlson, PhD, President…

SEATTLE, May 18, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that SeptiCyte™ LAB outperformed other clinical and laboratory parameters at distinguishing infection-negative systemic inflammation response syndrome (SIRS) from infection-positive systemic inflammation (sepsis). The data from the VENUS study were presented by Dr. Russell R. Miller, III…

Results of a Pilot Study of SeptiCyte™ LAB in the Pediatric Setting Published in Critical Care Medicine SEATTLE, Sept. 22, 2016 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and patients at risk of sepsis, announced today the publication, in Critical Care Medicine, of data demonstrating the ability…